- Previous Close
3.8700 - Open
3.8900 - Bid 3.9000 x --
- Ask 4.1000 x --
- Day's Range
3.8000 - 4.0000 - 52 Week Range
3.5100 - 7.5000 - Volume
14,900 - Avg. Volume
9,348 - Market Cap (intraday)
64.313M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.30
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis. Abera Bioscience AB was incorporated in 2012 and is based in Uppsala, Sweden.
aberabio.comRecent News: ABERA.ST
View MorePerformance Overview: ABERA.ST
Trailing total returns as of 11/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABERA.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABERA.ST
View MoreValuation Measures
Market Cap
59.41M
Enterprise Value
56.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.75
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-82.39%
Return on Assets (ttm)
-47.08%
Return on Equity (ttm)
-98.58%
Revenue (ttm)
9.26M
Net Income Avi to Common (ttm)
-7.63M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
2.63M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.6M